Payment overview · 2025
General Payments
$290.59
14 reported records · 9 companies
Healthcare provider profile · identity verified
Romano Nteela Abuaba, MD
Allopathic & Osteopathic Physicians|Internal Medicine · AURORA, CO · NPI 1295014710
Verified facts
What the public records show
CMS Open Payments records show Romano Nteela Abuaba, MD received $290.59 in general payments during 2025 across 14 reported records.
Lilly USA, LLC accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.33 | 18.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.97 | 15.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $39.09 | 13.4% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $31.08 | 10.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.00 | 10.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.98 | 8.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.93 | 8.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.03 | 7.6% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.18 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $290.59 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.33 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.33 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $43.97 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $31.08 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.98 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
112 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
81 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 843 | 148 |
| Eliquis | Apixaban | 749 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 658 | 112 |
| Metoprolol Succinate | Metoprolol Succinate | 538 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 493 | 79 |
| Furosemide | Furosemide | 492 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 425 | 92 |
| Lisinopril | Lisinopril | 396 | 79 |
| Losartan Potassium | Losartan Potassium | 341 | 62 |
| Sertraline Hcl | Sertraline Hcl | 328 | 43 |
| Metformin Hcl | Metformin Hcl | 283 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 278 | 65 |
| Potassium Chloride | Potassium Chloride | 268 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 257 | 55 |
| Risperidone | Risperidone | 246 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 240 | 50 |
| Alendronate Sodium | Alendronate Sodium | 188 | 35 |
| Simvastatin | Simvastatin | 174 | 31 |
| Finasteride | Finasteride | 169 | 31 |
| Olanzapine | Olanzapine | 167 | 24 |
| Gabapentin | Gabapentin | 163 | 43 |
| Myrbetriq | Mirabegron | 162 | 16 |
| Spironolactone | Spironolactone | 162 | 32 |
| Tradjenta | Linagliptin | 160 | 16 |
| Bumetanide | Bumetanide | 149 | 21 |
| Carvedilol | Carvedilol | 141 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 33 |
| Omeprazole | Omeprazole | 137 | 39 |
| Famotidine | Famotidine | 130 | 15 |
| Trazodone Hcl | Trazodone Hcl | 130 | 35 |
| Mirtazapine | Mirtazapine | 127 | 31 |
| Jardiance | Empagliflozin | 122 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 25 |
| Xarelto | Rivaroxaban | 112 | 18 |
| Lamotrigine | Lamotrigine | 111 | 12 |
| Clozapine | Clozapine | 105 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 24 |
| Latanoprost | Latanoprost | 97 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 21 |
| Allopurinol | Allopurinol | 94 | 21 |
| Levetiracetam | Levetiracetam | 91 | suppressed |
| Pregabalin | Pregabalin | 90 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 44 |
| Metformin Hcl Er | Metformin Hcl | 85 | suppressed |
| Aripiprazole | Aripiprazole | 84 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 84 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 20 |
| Trulicity | Dulaglutide | 81 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 24 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 79 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 71 | 29 |
| Divalproex Sodium | Divalproex Sodium | 69 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 14 |
| Spiriva Handihaler | Tiotropium Bromide | 66 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 12 |
| Meloxicam | Meloxicam | 60 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 24 |
| Lactulose | Lactulose | 57 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 11 |
| Prednisone | Prednisone | 57 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 12 |
| Bupropion Xl | Bupropion Hcl | 51 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 50 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 49 | suppressed |
| Rytary | Carbidopa/Levodopa | 49 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Topiramate | Topiramate | 48 | suppressed |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 45 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Amantadine | Amantadine Hcl | 44 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 42 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Baclofen | Baclofen | 38 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 25 |
| Glipizide | Glipizide | 35 | 12 |
| Ceftriaxone | Ceftriaxone Sodium | 34 | 17 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 33 | 32 |
| Prazosin Hcl | Prazosin Hcl | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 22 |
| Cephalexin | Cephalexin | 31 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 19 |
| Lurasidone Hcl | Lurasidone Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 15 |
| Methimazole | Methimazole | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 15 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 29 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 28 | 14 |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 15 |
| Primidone | Primidone | 25 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Nystatin | Nystatin | 24 | 20 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | 11 |
| Rasagiline Mesylate | Rasagiline Mesylate | 22 | suppressed |
| Clozapine Odt | Clozapine | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Droxia | Hydroxyurea | 19 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 19 | suppressed |
| Lorazepam Intensol | Lorazepam | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Nystop | Nystatin | 17 | 14 |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | 11 |
| Anastrozole | Anastrozole | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 14 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Acetic Acid | Acetic Acid | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Fluorometholone | Fluorometholone | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Glucagon Emergency Kit | Glucagon | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Orencia | Abatacept | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $290.59 · 14 records | Lilly USA, LLC | CAPVAXIVE, GARDASIL 9, GEMTESA, INGREZZA, MOUNJARO, NUPLAZID, REXULTI, SPRAVATO, VRAYLAR, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error